Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Cardiol Ther ; 11(3): 369-384, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35933641

ABSTRACT

Cardiogenic shock (CS) remains a leading cause of morbidity and mortality among patients with cardiovascular disease. In the past, acute myocardial infarction was the leading cause of CS. However, in recent years, other etiologies, such as decompensated chronic heart failure, arrhythmia, valvular disease, and post-cardiotomy, each with distinct hemodynamic profiles, have risen in prevalence. The number of treatment options, particularly with regard to device-mediated therapy has also increased. In this review, we sought to survey the medical literature and provide an update on current practices.

2.
J Interv Card Electrophysiol ; 63(2): 295-302, 2022 Mar.
Article in English | MEDLINE | ID: mdl-33770337

ABSTRACT

BACKGROUND: Catheter ablation (CA) is indicated as definitive therapy for patients with either typical or atypical atrial flutter (TAFlutter and AAFlutter, respectively) which is unresponsive to medical therapy. There is a paucity of data regarding in-hospital outcomes of patients undergoing CA. METHODS: Retrospective study using the NIS to identify patients ≥18 years who underwent CA between 2015 and 2017. Individuals were identified using ICD-10-CM/PCS for TAFlutter, AAFlutter, and CA. RESULTS: A total of 17,390 patients underwent CA for Aflutter (33% AAFlutter and 67% TAFlutter). The TAFlutter group was younger (mean 65.9 years vs. 67.2 years), with less females (30% vs. 43%, p ≤ 0.001 for both) compared to the AAFlutter group. The TAFlutter group had a higher rate of diabetes, tobacco use, obesity, and chronic obstructive pulmonary disease (p ≤ 0.001 for all). The AAFlutter cohort had increased prior strokes and atrial fibrillation (p ≤ 0.001 for both). The mean CHA2DS2-VASc score was found to be 2.3 in AAFlutter compared to 2.1 in TAFlutter (p ≤ 0.001). There were significantly higher proportions of thromboembolic events, transfusions, and longer length of stay in the TAFlutter group (p ≤ 0.001 for all) with the AAFlutter group having significantly higher rates of cardioversion, implantation of cardiac devices, and increased hospital charges (p ≤ 0.001 for all); no significant difference was found in mortality after controlling for comorbidities. CONCLUSIONS: We found higher complication rates in CA for patients with TAFlutter, but no difference in in-hospital all-cause mortality. Variation in CA depending upon the mechanism of AFlutter may underlie these differences, and warrant further study.


Subject(s)
Atrial Fibrillation , Atrial Flutter , Catheter Ablation , Atrial Fibrillation/therapy , Atrial Flutter/etiology , Catheter Ablation/adverse effects , Female , Hospitals , Humans , Retrospective Studies
3.
Am J Cardiol ; 162: 6-12, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34711393

ABSTRACT

Takotsubo syndrome (TTS) largely affects postmenopausal women but has been shown to carry increased mortality risk in men. We sought to evaluate nationwide in-hospital outcomes between men and women admitted with TTS to better characterize these disparities. Using the National Inpatient Sample database from 2011 to 2018, we identified a total of 48,300 hospitalizations with the primary diagnosis of TTS. The primary end point was in-hospital all-cause mortality. Secondary end points included in-hospital complications, length of stay, and discharge disposition. Men with TTS accounted for 8.9% of hospitalizations, were younger in age (62.0 ± 15.1 vs 66.8 ± 12.1 years, p <0.001), and were more frequently Black (9.7% vs 5.8%, p <0.001). Nationwide TTS mortality rates were 1.1% overall and may be improving, but remained higher in men than in women (2.2% vs 1.0%, p <0.001). Male gender was associated with increased all-cause mortality (adjusted odds ratios 2.41, 95% confidence interval 1.88 to 3.10, p <0.001), greater length of stay, and discharge complexity. Men carried increased co-morbidity burden associated with increased cardiogenic shock or mortality, including atrial fibrillation, thrombocytopenia, chronic kidney disease, and chronic obstructive pulmonary disease. Men more frequently developed acute kidney injury, ventricular arrhythmias, cardiac arrest, and respiratory failure. Male gender remains associated with nearly 2.5-fold increase in in-hospital mortality risk. In conclusion, early identification of patients with high-risk co-morbidities and close monitoring for arrhythmias, renal injury, or cardiogenic shock may reduce morbidity and mortality.


Subject(s)
Takotsubo Cardiomyopathy/complications , Takotsubo Cardiomyopathy/mortality , Age Factors , Aged , Databases, Factual , Female , Hospital Mortality , Hospitalization , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Sex Factors , Survival Rate , Takotsubo Cardiomyopathy/diagnosis , United States
4.
Int J Artif Organs ; 45(4): 379-387, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34719291

ABSTRACT

INTRODUCTION: Due to the inability to keep up with the demand for heart transplantation, there is an increased utilization of left ventricular assist devices (LVAD). However, paucity of data exists regarding the association of household income with in-hospital outcomes after LVAD implantation. METHODS: Retrospective cohort study using the NIS to identify all patients ⩾18 years who underwent LVAD implantation from 2011 to 2017. Statistical analysis was performed comparing low household income (⩽50th percentile) and high income (>50th percentile). RESULTS: A total of 25,503 patients underwent LVAD implantation. The low-income group represented 53% and the high-income group corresponded to 47% of the entire cohort. The low-income group was found to be younger (mean age 55 ± 14 vs 58 ± 14 years), higher proportion of females (24% vs 22%), and higher proportion of blacks (32% vs 16%, p < 0.001 for all). The low-income group was found to have higher prevalence of hypertension, chronic pulmonary disease, smoking, dyslipidemia, obesity, and pulmonary hypertension (p < 0.001 for all). However, the high-income cohort had higher rate of atrial tachyarrhythmias and end-stage renal disease (p < 0.001). During hospitalization, patients in the high-income group had increased rates of ischemic stroke, acute kidney injury, acute coronary syndrome, bleeding, and need of extracorporeal membrane oxygenation (p < 0.001 for all). We found that the unadjusted mortality had an OR 1.30 (CI 1.21-1.41, p < 0.001) and adjusted mortality of OR 1.14 (CI 1.05-1.23, p = 0.002). CONCLUSION: In patients undergoing LVAD implantation nationwide, low-income was associated with increased comorbidity burden, younger age, and fewer in-hospital complications and all-cause mortality.


Subject(s)
Extracorporeal Membrane Oxygenation , Heart Failure , Heart-Assist Devices , Adult , Aged , Female , Heart Failure/surgery , Heart-Assist Devices/adverse effects , Hospitals , Humans , Middle Aged , Retrospective Studies , Treatment Outcome
5.
Thromb Res ; 202: 184-190, 2021 06.
Article in English | MEDLINE | ID: mdl-33892219

ABSTRACT

INTRODUCTION: Chronic liver disease (CLD) and advanced heart failure (HF) often co-exist with coagulopathy and hematologic abnormalities being major concerns in this cohort. Perioperative outcomes of patients undergoing LVAD implantation can be affected by coagulopathy, associated with a higher International Normalized Ratio (INR) and cytopenias, as well as pre-operative use of antiplatelet therapy and systemic anticoagulation. Our study is aimed at evaluating the in-hospital mortality and clinical outcomes of patients with CLD who underwent LVAD implantation compared to patients who underwent LVAD implantation without CLD. METHODS: The National Inpatient Sample Database was queried from 2012 to 2017 for relevant International Classification of Diseases (ICD)-9 and ICD-10 procedural and diagnostic codes. Baseline characteristics and in-hospital outcomes were compared in patients with chronic liver disease and those without, who underwent LVAD implantation. RESULTS: A total of 22,955 patients underwent LVAD implantation, 2200 of which had CLD. There was no difference in mean age between those with and without CLD (52.8 ± 14.2 vs. 55.7 ± 15.4 years old, p < 0.001), and 23.7% of patients were female. The proportion of patients with CLD undergoing LVAD implantation trended downward between 2012 and 2017 (average annual growth rate: "-14.8%"). In-hospital post-LVAD outcomes revealed: all-cause inpatient mortality (14.8% vs. 11.1%), major bleeding (34.3% vs. 30.2%), transfusion of platelets (18.0% vs. 14.0%), subarachnoid hemorrhage (1.6% vs. 0.7%) and hospital length of stay were greater in patients with CLD (p < 0.001 for all values). LVAD thrombosis (6.6% vs. 9.4%) and postoperative ischemic stroke (3.4% vs. 6.1%) occurred less in patients with CLD (p < 0.001 for both). There were no statistically significant differences in occurrence of post-LVAD gastrointestinal bleeding and transfusion of fresh frozen plasma or packed red blood cells (p > 0.05 for all). Using a multivariate logistic regression model to adjust for confounding factors, CLD was predictive of increased in-hospital all-cause mortality in patients undergoing LVAD implantation (adjusted odds ratio: 1.29, 95% confidence interval [CI]; 1.06 to 1.56, p = 0.010). CONCLUSION: LVAD implantation in patients with chronic liver disease was associated with increased mortality and post-LVAD major bleeding with increased utilization of platelet products yet comparable thrombotic complications. Further studies are needed to evaluate the balance and pathophysiology of bleeding risks when compared to thrombosis, as well as predictors in patients with chronic liver disease.


Subject(s)
Heart-Assist Devices , Liver Diseases , Thrombosis , Adult , Aged , Female , Hospitals , Humans , Male , Middle Aged , Retrospective Studies
6.
Am J Cardiol ; 148: 94-101, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33684373

ABSTRACT

Prior studies have shown that the early inclusion of palliative care (PC) specialist is associated with better end-of-life experiences. The National Inpatient Sample Database was queried from 2012 to 2017 for relevant of ICD)-9 and -10 procedural and diagnostic codes to identify patients above 18 years with advanced heart failure (HF) admitted with cardiogenic shock (CS) requiring mechanical circulatory support (MCS). Baseline characteristics, utilization trends and invasive procedures and complications were compared among patients evaluated by PC and those who were not. There were 65,230 patients hospitalized for advanced HF complicated by CS requiring MCS, of these a PC consult was placed in in 9,200 patients (14.1%) and trended upward from 9.4 to 16.8%, between 2012 to 2017. The majority of patients, (37.3%) from the total population died in hospital. In reference to patients who were discharged alive, PC consultation was associated with a lower incidence of invasive procedures such as mechanical ventilation, pacemaker implantation, defibrillator implantation, insertion of percutaneous feeding tubes and tracheostomies performed (p <0.05 for all) whereas complications such as major bleeding, septic shock, transfusion of any blood product were comparable between both cohorts (nonsignificant p value for all). On the other hand, in those patients who died in hospital PC was associated with a lower incidence of pacemaker implantation, defibrillator implantation and insertion of percutaneous feeding tubes (p <0.05 for all). Despite the high morbidity and mortality associated with advanced HF patients with CS requiring MCS, the overall prevalence of PC consultation is exceedingly low. When utilized, the incidence of invasive procedures was lower. This study highlights the underutilization of PC services in this patient population, precluding any perceived benefit in end-of-life experiences.


Subject(s)
Assisted Circulation , Extracorporeal Membrane Oxygenation , Heart Failure/therapy , Palliative Medicine , Referral and Consultation/statistics & numerical data , Shock, Cardiogenic/therapy , Age Factors , Aged , Aged, 80 and over , Coronary Artery Disease/epidemiology , Defibrillators, Implantable , Enteral Nutrition , Female , Gastrostomy , Heart Failure/epidemiology , Heart-Assist Devices , Hospital Mortality , Humans , Intra-Aortic Balloon Pumping , Logistic Models , Male , Middle Aged , Pacemaker, Artificial , Prosthesis Implantation , Sex Factors , Shock, Cardiogenic/epidemiology
7.
Heart Rhythm ; 18(6): 987-994, 2021 06.
Article in English | MEDLINE | ID: mdl-33588068

ABSTRACT

BACKGROUND: Select patients with atrial fibrillation and contraindication to anticoagulation may benefit from percutaneous left atrial appendage closure (pLAAC). OBJECTIVE: The purpose of this study was to evaluate racial disparities in the nationwide utilization and outcomes of pLAAC. METHODS: We identified 16,830 hospitalizations for pLAAC between 2015 and 2017 using the National Inpatient Sample. Baseline characteristics, in-hospital mortality, complications, length of stay, and discharge disposition were assessed between White and Black/African American (AA) populations. RESULTS: Black/AA patients represented 4.1% of nationwide pLAAC recipients and were younger, more likely to be female, and had greater prevalence of hypertension, heart failure, hyperlipidemia, obesity, chronic kidney disease, and prior stroke history (P <.001 for all). Black/AA patients had significantly increased length of stay and nonroutine discharge (P <.001 for both) but comparable in-hospital mortality to White patients. Black/AA patients suffered from greater postoperative stroke (0.7% vs 0.2%), acute kidney injury (4.5% vs 2.1%), bleeding requiring transfusion (4.5% vs 1.4%), and venous thromboembolism (0.7% vs 0.1%; P <.01 for all). After controlling for possible confounding factors, Black/AA race was independently associated with significantly increased odds of bleeding requiring blood transfusion, stroke, venous thromboembolism, and nonroutine discharge. CONCLUSION: Among pLAAC recipients nationwide, Black/AA populations were underrepresented and had greater complication rates, length of stay, and discharge complexity. This study highlights the importance of addressing ongoing racial disparities in both utilization and outcomes of pLAAC.


Subject(s)
Atrial Appendage/surgery , Atrial Fibrillation/ethnology , Cardiac Surgical Procedures/standards , Healthcare Disparities , Hospitals/statistics & numerical data , Racial Groups , Stroke/prevention & control , Aged , Atrial Fibrillation/complications , Atrial Fibrillation/physiopathology , Cardiac Catheterization , Female , Follow-Up Studies , Hospital Mortality/trends , Humans , Incidence , Male , Retrospective Studies , Risk Factors , Stroke/ethnology , Stroke/etiology , United States/epidemiology
8.
Am J Cardiol ; 142: 109-115, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33285093

ABSTRACT

A history of malignancy is incorporated in the Society of Thoracic Surgeons score to assess presurgical risk in patients undergoing surgical aortic valve replacement, however data on the prognostic importance in those undergoing transcatheter aortic valve implantation (TAVI) remains limited. We sought to investigate the utilization and in-hospital outcomes of TAVI in patients with a history of malignancy. The National Inpatient Sample Database was queried from 2012 to 2017 to identify patients who underwent TAVI using International Classification of Diseases (ICD) 9 and ICD-10 procedure codes. Between 2012 and 2017, there were 123,070 patients who underwent TAVI, of these 23,670 patients (19.2%) had a previous history of malignancy. The proportion of patients undergoing TAVI with a history of malignancy trended upward between 2012 and 2017. Patients with a history of malignancy were similar in age to those without (81.1 ± 7.9 vs 80.1 ± 6.7 years old, p <0.001), with a higher prevalence of tobacco use and major depressive disorder (p <0.001 for both). Patients with a history of malignancy had higher rates of post-TAVI pacemaker implantation (p <0.001), otherwise periprocedural complication rates were similar to those without. Using a multivariate logistic regression model to adjust for confounding factors, a history of malignancy was predictive of decreased odds of death in patients underwent TAVI (OR: 0.67, 95% CI, 0.60 to 0.76, p <0.001) and higher odds of pacemaker implantation (OR: 1.14, 95% CI, 1.09 to 1.19, p <0.001). In conclusion, with time the proportion of TAVI patients with a history of malignancy trended upward. Despite a greater prevalence of previous tobacco use and major depressive disorder, patients with a history of malignancy had TAVI safely with a low in-hospital all-cause mortality, yet greater cost of hospitalization and more frequent implantation of pacemaker devices.


Subject(s)
Aortic Valve Stenosis/surgery , Cardiac Conduction System Disease/epidemiology , Hospital Mortality , Neoplasms/epidemiology , Postoperative Complications/epidemiology , Transcatheter Aortic Valve Replacement , Aged , Aged, 80 and over , Aortic Valve Stenosis/epidemiology , Cardiac Conduction System Disease/therapy , Cardiac Pacing, Artificial/statistics & numerical data , Case-Control Studies , Depressive Disorder, Major/epidemiology , Female , Health Care Costs , Humans , Logistic Models , Male , Multivariate Analysis , Pacemaker, Artificial , Postoperative Complications/therapy , Prevalence , Smoking/epidemiology , United States/epidemiology
9.
J Card Surg ; 35(12): 3374-3380, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33001502

ABSTRACT

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a cause of ventricular dysfunction. However, in the setting of patients with heart failure undergoing left ventricular assist device (LVAD) implantation, there is a paucity of data on the association between COPD and in-hospital outcomes. METHODS AND RESULTS: Retrospective cohort study based on the NIS including patients ≥18 years who underwent LVAD implantation from 2011 to 2017. Multivariate regression was used to evaluate the impact of COPD on in-hospital outcomes. A total of 25,503 patients underwent LVAD implantation, of which 13.8% also had COPD. COPD group was older (median 62 vs. 58 years), and more males (82% vs. 76.4%, p < .001 for both). COPD group had more hypertension, diabetes, atrial tachyarrhythmias, dyslipidemia, prior stroke, coronary artery diseases, pulmonary hypertension, and chronic kidney disease (p < .001 for all). No differences in strokes, infections, mechanical circulatory support, and LVAD thrombosis. There was a higher incident of inpatient acute kidney injury, major bleeding, cardiac complications, thromboembolism, and cardiac arrest in patients without COPD (p < .05 for all). Compared with no-COPD group, COPD group had a lower mortality (6.2% vs. 12.4%; odds ratio, 0.59; confidence interval, 0.512-0.685; p < .05). CONCLUSION: Patients with COPD undergoing LVAD implantation have more comorbidities, without an associated increase mortality.


Subject(s)
Heart Failure , Heart-Assist Devices , Pulmonary Disease, Chronic Obstructive , Hospitals , Humans , Male , Pulmonary Disease, Chronic Obstructive/complications , Retrospective Studies , Treatment Outcome
10.
Int J Cardiol ; 307: 166-170, 2020 05 15.
Article in English | MEDLINE | ID: mdl-32067836

ABSTRACT

BACKGROUND: Recent data suggest that population screening for risk of sudden cardiac death (SCD) may be feasible with risk scores that can be implemented in the electronic health record. But, there are no established therapeutic strategies to target lowering risk for SCD in the general population. Our aim was to evaluate the effect of the Systolic Blood Pressure Intervention Trial (SPRINT) intensive blood pressure intervention on SCD risk and cardiovascular (CV) outcomes. METHODS: We conducted a prospective cohort study within the SPRINT trial including all participants who had information required to calculate a SCD score. We classified SPRINT participants at baseline by randomized arm into high, intermediate and low SCD risk and followed them for a period of 12 months. We determined changes in SCD risk by comparing the baseline SCD risk score with the 12-month recalculated SCD risk score and determined the incidence of the primary SPRINT outcome and all-cause mortality. We used both linear regression and Cox proportional models to evaluate outcomes adjusted for CV risk, prevalent CV diseases, and randomization site. RESULTS: We included 8052 SPRINT participants who met our inclusion criteria. The median baseline SCD score was 2.7% SCD per 10 years; 95% CI 1.6 to 4.7 for both randomized arms. At 12-month follow-up, the median SCD score for the intensive group was 5.5 (2.0-20) while the standard group was 6.8 (2.4-26) p<0.01. Over a follow-up period of 3.8 years, in the intensive arm, the HR for those who had a reduction in SCD risk score was 0.80; 95% CI 0.62-0.98 for the primary event while the HR for the standard arm was 1.01; 95% CI 0.81-1.26. The changes in SCD risk were mediated by decreases in blood pressure and an increase in diabetes incidence as well as age. CONCLUSIONS: SCD risk changed in SPRINT because of intensive blood pressure control and those who changed their score had fewer cardiovascular events. Future studies should target comprehensive interventions targeting all modifiable risk factors.


Subject(s)
Antihypertensive Agents , Hypertension , Antihypertensive Agents/therapeutic use , Blood Pressure , Humans , Hypertension/diagnosis , Hypertension/drug therapy , Hypertension/epidemiology , Prospective Studies , Risk Factors
11.
Oxf Med Case Reports ; 2018(9): omy075, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30159160

ABSTRACT

Pericardial disease is a common complication of solid tumors and occasionally seen in hematologic malignancies. Pericardial effusion, when it occurs, is usually caused by tumor seeding of the pericardium leading to a serous effusion or by mass effect from mediastinal lymphadenopathy blocking drainage of lymphatic ducts. Pericardial disease from non-Hodgkin's lymphoma is uncommon and malignant pericardial effusion is even rarer. Here we present a case of a 31-year-old male with diffuse large B-cell lymphoma who developed cardiac tamponade from a malignant pericardial effusion.

SELECTION OF CITATIONS
SEARCH DETAIL
...